Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 14, 2025—AbbVie announced that Emrelis (telisotuzumab vedotin-tllv) has been granted accelerated approval by the FDA for the treatment of adult patients with locally advanced or metastatic, nonsquamous non-small cell lung cancer with high c-Met protein overexpression who have received a prior systemic therapy.
May 8, 2025—Ibex Medical Analytics reports that a study conducted at Ohio State University Wexner Medical Center confirms that Ibex Breast, an AI-powered diagnostic support solution, significantly improves accuracy and efficiency in evaluating breast pathology cases (Tahir M, et al. Clin Breast Cancer. Published online March 26, 2025).
April 29, 2025—Roche announced that the FDA granted breakthrough device designation for the Ventana TROP2 (EPR20043) RxDx device, a computational pathology device.
April 24, 2025—Techcyte announced the launch of its wet mount iodine solution for research use only in the United States.
April 23, 2025—ARUP Laboratories now provides a blood test for phosphorylated tau 217 to assist in identifying whether symptoms of cognitive decline in patients ages 60 years and older are related to Alzheimer’s disease pathology.
April 23, 2025—ARUP Laboratories now provides a blood test for phosphorylated tau 217 to assist in identifying whether symptoms of cognitive decline in patients ages 60 years and older are related to Alzheimer’s disease pathology.
April 21, 2025—Diasorin announced it has received FDA 510(k) clearance for the Liaison Plex Gram-Negative Blood Culture assay, the second of the company’s three multiplex molecular panels for blood culture pathogen identification on the Liaison Plex.
April 11, 2025—BD announced FDA 510(k) clearance for the BD Phoenix M50 automated microbiology solution and BDXpert system on the BD Synapsys informatics solution, leveraging rapid identification and antimicrobial susceptibility testing algorithms to assist in the interpretation of complex diagnostic data to help ensure accurate and reliable diagnoses related to antimicrobial resistance.
April 8, 2025—Techcyte, Pramana, and Aiosyn, announced a collaboration to integrate AI-powered breast and kidney histopathology analysis directly into a digital pathology workflow.
April 4, 2025—Paige announced that the FDA has granted breakthrough device designation to Paige PanCancer Detect, an AI-assisted diagnostic application intended to assist pathologists in the detection of foci that are suspicious for cancer from multiple tissues and organs.
